Drug price scandals aren’t all the same - but here’s one that may be preventable.
It's surprisingly hard to figure out how much oncologists make from office-infused drugs, but we gave it our best shot.
Pharma CEOs boast of trimming headcount and boosting productivity. Spoiler alert: they're not.
Critics claim pharma is skimping on research spending - but the data say otherwise.
Should FDA automatically approve drugs available in other countries? The potential clinical benefits may be overstated.
New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects.